Pacira Biosciences, Inc. (PCRX)
36.38
-0.01
(-0.03%)
USD |
NASDAQ |
Oct 29, 16:00
36.38
0.00 (0.00%)
After-Hours: 16:50
Pacira Biosciences Enterprise Value : 1.610B for Oct. 28, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 28, 2026 | 1.610B |
| October 27, 2026 | 1.611B |
| October 26, 2026 | 1.610B |
| October 23, 2026 | 1.611B |
| October 22, 2026 | 1.608B |
| October 21, 2026 | 1.608B |
| October 20, 2026 | 1.610B |
| October 19, 2026 | 1.608B |
| October 16, 2026 | 1.608B |
| October 15, 2026 | 1.608B |
| October 14, 2026 | 1.611B |
| October 13, 2026 | 1.607B |
| October 12, 2026 | 1.609B |
| October 09, 2026 | 1.607B |
| October 08, 2026 | 1.610B |
| October 07, 2026 | 1.165B |
| October 06, 2026 | 1.147B |
| October 05, 2026 | 1.159B |
| October 02, 2026 | 1.165B |
| October 01, 2026 | 1.157B |
| September 30, 2026 | 1.159B |
| September 29, 2026 | 1.183B |
| September 28, 2026 | 1.172B |
| September 25, 2026 | 1.161B |
| September 24, 2026 | 1.179B |
| Date | Value |
|---|---|
| September 23, 2026 | 1.142B |
| September 22, 2026 | 1.145B |
| September 21, 2026 | 1.121B |
| September 18, 2026 | 1.144B |
| September 17, 2026 | 1.136B |
| September 16, 2026 | 1.153B |
| September 15, 2026 | 1.120B |
| September 14, 2026 | 1.144B |
| September 11, 2026 | 1.171B |
| September 10, 2026 | 1.163B |
| September 09, 2026 | 1.192B |
| September 08, 2026 | 1.191B |
| September 04, 2026 | 1.210B |
| September 03, 2026 | 1.220B |
| September 02, 2026 | 1.220B |
| September 01, 2026 | 1.215B |
| August 31, 2026 | 1.192B |
| August 28, 2026 | 1.187B |
| August 27, 2026 | 1.190B |
| August 26, 2026 | 1.192B |
| August 25, 2026 | 1.178B |
| August 24, 2026 | 1.151B |
| August 21, 2026 | 1.144B |
| August 20, 2026 | 1.110B |
| August 19, 2026 | 1.131B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Viatris, Inc. | 33.90B |
| Liquidia Corp. | 3.972B |
| Organon & Co. | 11.04B |
| ANI Pharmaceuticals, Inc. | 1.882B |
| Corcept Therapeutics, Inc. | 9.013B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 4.653M |
| Revenue (Quarterly) | 192.40M |
| Total Expenses (Quarterly) | 187.75M |
| EPS Diluted (Quarterly) | 0.1155 |
| Gross Profit Margin (Quarterly) | 69.60% |
| Profit Margin (Quarterly) | 2.42% |
| Earnings Yield | 0.95% |
| Operating Earnings Yield | 1.80% |
| Normalized Earnings Yield | 1.339 |